Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)

This Phase II study is testing whether adding low-dose radiation therapy to an immunotherapy drug called adebrelimab plus standard chemotherapy improves outcomes for patients with extensive-stage small cell lung cancer — one of the most aggressive forms of lung cancer. Low-dose radiation is thought to help the immune system recognize and attack the tumor more effectively. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed with extensive-stage small cell lung cancer (spread beyond one lung) - You have not previously received chemotherapy or radiation for this cancer - You are in good general health (ECOG 0–1) - Your expected survival is at least 8 weeks **You may NOT be eligible if...** - Your lung cancer is a mix of small cell and non-small cell types - You had major surgery within the past 28 days - You received a live vaccine within the past 28 days - You have active autoimmune conditions or uncontrolled infections Talk to your doctor to see if this trial is right for you.